Glenmark to launch anti-hypertension drug in US, gets USFDA nod

Tags: Companies
Glenmark Pharmaceuticals will launch generic version of anti-hypertension drug telmisartan tablets in the US market following receipt of approval from the country's health regulator.

Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Ltd has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets, the company said in a filing to the BSE.

"Glenmark will commence distribution of the product immediately," it added.

The approval is for the 20 mg, 40 mg and 80 mg tablets.

Telmisartan tablets are Glenmark's generic version of Boehringer Ingelheim's Micardis. Telmisartan is indicated for the treatment of hypertension.

For the 12-month period ended March 2014, Telmisartan garnered annual sales of USD 250 million, according to IMS Health, the company said.

Glenmark's current portfolio consists of 92 products authorised for distribution in the US market and 73 ANDAs are pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 595.60 per scrip in the mid-day trade, up 1.09 per cent from the previous close on the BSE.

EDITORIAL OF THE DAY

  • RBI's new lending norms to clean up bank books, check defaults

    As state-owned banks come closer to cleaning up their balancesheet by March next year, the Reserve Bank of India (RBI) has started another major refor

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

BK Chaturvedi

Governance is under serious attack

The prosecution of an extraordinarily honest civil servant like HC ...

Rajgopal Nidamboor

It is not easy to define emotion

Scientists, who analyse straightforward scientific facts, also recognise and comprehend ...

Dharmendra Khandal

Everything has its place in nature

Last week I was observing an injured animal, because of ...